山梨医科大学雑誌　第4巻2号　055-059(1989)

Anti-Platelet Action of Gliclazide, an Oral Hypoglycemic Agent, and its Possible Mechanism

Masato TAWATA, Kaoru AIDA, Hideo SHINDO, and Toshimasa ONAYA

Abstract: Hyperaggregability of platelets observed in diabetic patients has been speculated as one of the causes of chronic diabetic complications. Gliclazide, an oral hypoglycemic agent, inhibited the platelet aggregation, ATP release, the phosphorylation of 40 K dalton protein and a thrombin-induced increase of intraplatelet calcium in vitro. Although a high concentration of gliclazide (500 μg/ml) was required to inhibit the increase of intraplatelet calcium induced by O.1 U/ml thrombin, the inhibitory effect of gliclazide on platelet aggregation induced by 0.5 μg/ml collagen, was observed at a concentration as low as 1 μg/ml.
The results of our experiments demonstrated that gliclazide directly inhibits the platelet aggregation at a concentration attainable by the usual oral dose of gliclazide. Therefore, it is likely that gliclazide has a favorable action on diabetic complications, not only by reducing blood glucose level, but also by reducing platelet hyperaggregability.

Key words: Gliclazide, oral hypoglycemic agent, Anti-platelet action, Diabetic complications




本文は、編集委員会の意向によりインターネットには公開しておりません。図書館等でご覧ください。

Texts are not availavle on Internet.



目次・Contentsに戻る